Filing Flows › Health Care › Rhythm Pharmaceuticals (RYTM)
Rhythm Pharmaceuticals (RYTM) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 3, 2026 · Rhythm Pharmaceuticals (RYTM) Q3 2026 earnings results →
Q3 2026 Revenue up 80% year over year to $92.1M · 45¢ of every $1 of revenue lost · operating margin -42.6%
Rhythm Pharmaceuticals made $92.1M in Q3 2026 (+80% Y/Y). Operating margin -42.6%, net loss $41.4M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 3, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $92.1M in Q3 2026, up 80% year over year and up 29% from the previous quarter.
Operating costs exceeded revenue by $39.3M, an operating margin of -42.6%. Total costs grew 26% against revenue growth of 80%. The fastest-growing cost line was Cost of revenue (+121%). The quarter ended with a net loss of $41.4M, narrower than the previous quarter's $49.3M loss.
Operating cash flow was −$3.1M. Non-cash charges added back $25.0M of share-based compensation. Working capital and other items added $13.3M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 3, 2026 | $92.1M | +80% | -42.6% | −$41.4M | −$3.1M |
| Q2 2026 | 10-Q | Aug 4, 2026 | $71.3M | +47% | -68.1% | −$49.3M | −$9.2M |
| Q1 2026 | 10-Q | May 5, 2026 | $60.1M | +84% | -87.1% | −$55.6M | −$44.2M |
| Q4 2025 | 10-K | Feb 26, 2026 | $57.3M | +37% | -82.2% | −$47.5M | −$25.4M |
| Q3 2025 | 10-Q | Nov 4, 2025 | $51.3M | +54% | -102.6% | −$52.9M | −$26.6M |
| Q2 2025 | 10-Q | Aug 5, 2025 | $48.5M | +67% | -93.4% | −$46.6M | −$23.3M |
| Q1 2025 | 10-Q | May 7, 2025 | $32.7M | +26% | -143.7% | −$49.5M | −$40.4M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Rhythm Pharmaceuticals
We are a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patients living with rare neuroendocrine diseases. We are focused on advancing melanocortin-4 receptor (MC4R) agonists, including our lead asset, IMCIVREE ® (setmelanotide), as precision medicines designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. While obesity affects hundreds of millions of people worldwide, we are developing therapies for a subset of individuals who have hyperphagia, a pathological, insatiable hunger and impaired satiety accompanied by persistent and abnormal food-seeking behaviors, decreased energy expenditure and severe obesity due to diseases such as acquired or congenital hypothalamic obesity, Bardet-Biedl syndrome (BBS), Prader-Willi syndrome (PWS) and other diseases caused by impaired MC4R pathway signaling.
In its own words, from its 10-K, filed Feb 26, 2026.
Rhythm Pharmaceuticals against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +80% against the peers' median +10%. Operating margin: -42.6% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| RYTM Rhythm Pharmaceuticals | Q3 2026 | $92.1M | +80% | -42.6% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Rhythm Pharmaceuticals 10-Q on SEC EDGAR · CIK 1649904 · Pharmaceutical Preparations
Guidance and outlook
13F: who owns RYTM and who is buying
More on RYTM
- How Rhythm Pharmaceuticals makes money: revenue by segment
- Rhythm Pharmaceuticals next earnings date and what analysts expect
- Rhythm Pharmaceuticals stock forecast, price target and fair value
- Who owns Rhythm Pharmaceuticals stock: holders, funds and Congress trades
- Rhythm Pharmaceuticals guidance and outlook
- Is Rhythm Pharmaceuticals a takeover target? LBO and rumors
- Rhythm Pharmaceuticals recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results